Your browser doesn't support javascript.
loading
Association between Ranolazine, Ischemic Preconditioning, and Cardioprotection in Patients Undergoing Scheduled Percutaneous Coronary Intervention.
Kourtis, Konstantinos; Bourazana, Angeliki; Xanthopoulos, Andrew; Skoularigkis, Spyridon; Papadakis, Emmanouil; Patsilinakos, Sotirios; Skoularigis, John.
Afiliación
  • Kourtis K; Department of Cardiology, Konstantopouleio General Hospital, 14233 Athens, Greece.
  • Bourazana A; Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece.
  • Xanthopoulos A; Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece.
  • Skoularigkis S; Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece.
  • Papadakis E; Department of Cardiology, Konstantopouleio General Hospital, 14233 Athens, Greece.
  • Patsilinakos S; Department of Cardiology, Konstantopouleio General Hospital, 14233 Athens, Greece.
  • Skoularigis J; Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece.
Medicina (Kaunas) ; 60(1)2024 Jan 16.
Article en En | MEDLINE | ID: mdl-38256425
ABSTRACT
Background and

Objectives:

Remote ischemic preconditioning (RIPC) has demonstrated efficacy in protecting against myocardial ischemia-reperfusion injury when applied before percutaneous coronary revascularization. Ranolazine, an anti-ischemic drug, has been utilized to minimize ischemic events in chronic angina patients. However, there is a lack of trials exploring the combined effects of ranolazine pretreatment and RIPC in patients undergoing percutaneous coronary interventions (PCIs). Materials and

Methods:

The present study is a prospective study which enrolled 150 patients scheduled for nonemergent percutaneous coronary revascularization. Three groups were formed a control group undergoing only PCIs, an RIPC group with RIPC applied to either upper limb before the PCI (preconditioning group), and a group with RIPC before the PCI along with prior ranolazine treatment for stable angina (ranolazine group). Statistical analyses, including ANOVAs and Kruskal-Wallis tests, were conducted, with the Bonferroni correction for type I errors. A repeated-measures ANOVA assessed the changes in serum enzyme levels (SGOT, LDH, CRP, CPK, CK-MB, troponin I) over the follow-up. Statistical significance was set at p < 0.05.

Results:

The ranolazine group showed (A) significantly lower troponin I level increases compared to the control group for up to 24 h, (B) significantly lower CPK levels after 4, 10, and 24 h compared to the preconditioning group (p = 0.020, p = 0.020, and p = 0.019, respectively) and significantly lower CPK levels compared to the control group after 10 h (p = 0.050), and (C) significantly lower CK-MB levels after 10 h compared to the control group (p = 0.050).

Conclusions:

This study suggests that combining RIPC before scheduled coronary procedures with ranolazine pretreatment may be linked to reduced ischemia induction, as evidenced by lower myocardial enzyme levels.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Precondicionamiento Isquémico / Intervención Coronaria Percutánea Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Medicina (Kaunas) Asunto de la revista: MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Grecia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Precondicionamiento Isquémico / Intervención Coronaria Percutánea Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Medicina (Kaunas) Asunto de la revista: MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Grecia